Abstract
To the Editor: The decision by the Food and Drug Administration (FDA) not to approve the use of 5α-reductase inhibitors as a means of preventing prostate cancer, as discussed by Theoret et al. (July 14 issue),1 illustrates the challenges that thwart efforts to develop agents for this purpose. To support its position, the FDA reanalyzed two major trials.2,3 It cited the fact that the incidence of tumors with modified Gleason scores between 7 and 10 was not reduced and that the absolute incidence of tumors with modified Gleason scores between 8 and 10 was increased by 0.7% with finasteride . . .
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
